A male factor is involved in 50% of infertile relationships. In particular, men with nonobstructive azoospermia cannot have their own biological children. The treatment is microdissection testicular sperm extraction, but the success rate is low, and new approaches for male infertility are needed. Stem cells have the potential to differentiate into different functional cell types, and their discovery has given rise to the field of regenerative medicine. We focus here on the therapeutic potential of stem cells for rejuvenating male fertility. Embryonic stem cells (ESCs) can differentiate directly into male or female gametes, but they are genetically unrelated to the patient. 
Introduction
The rate of pregnancy by intercourse in normal couples is 20-25% within one month, 75% within six months, and 90% within one year [1] . However, 15% of couples whose fertility status is unknown a priori are unable to conceive a baby after one year of intercourse without contraception. In 30% of these couples, the infertility is due to a significant male factor alone, whereas combined male and female factors are present in an additional 20% [2, 3, 4] . Thus, a male factor is involved in 50% of infertile relationships. In particular, men with nonobstructive azoospermia have little or no sperm in their semen, and cannot have their own biological children. Patients with nonobstructive azoospermia are typically characterized as having small-volume testes and elevated FSH. This condition is treated by microdissection testicular sperm extraction (micro-TESE) [5] . However, the success rate of micro-TESE for overcoming male infertility is not high. Therefore, novel approaches for treating male infertility are needed.
Stem cells have the potential to differentiate into different functional cell types, and their discovery has given rise to the fields of regenerative medicine and cloning.
Investigators have sought to develop methods using stem cells to correct or restore fertility. Embryonic stem cells have the potential to differentiate into nearly every cell type found in the body. As cells differentiate, they are thought to lose this plasticity; however, some tissues (the gastrointestinal, integumentary, spermatogenic, and hematopoietic systems) maintain their regenerative capacity. In fact, adult stem cells have been functionally identified in a wide range of tissues, and are thought to hold great promise for tissue regeneration. We focus here on the therapeutic potential of stem cells for the treatment of male fertility.
Embryonic stem cells
Embryonic stem cells are obtained from embryos, such as those generated during a routine in vitro fertilization (IVF) cycle. Until about the eight-cell stage, the blastomeres of fertilized embryos are totipotent; that is, they have the capacity to differentiate into any cell type in the body. Immediately thereafter, embryonic stem cells derived from the inner cell mass of a blastocyst become pluripotent, meaning they can differentiate into all cell types in the body, with the exception of placenta. These cells can be cultured under stringent conditions and expanded, yet maintain their regenerative capacity. Stem cell differentiation is controlled by both intrinsic genetic signals and extrinsic signals such as growth factors, cell contact, and the microenvironment or niche. Depending upon the culture conditions in vitro or the specific niche into which they are transplanted in vivo, the cells can be directed to differentiate into specific cell lineages.
The transplantation of undifferentiated embryonic stem cells results in teratoma formation, and indeed, the first observation of stem-cell-like activity occurred during studies of embryonal carcinoma cells. Scientists are beginning to dissect the patterns of gene expression and extrinsic modulators that regulate each step of embryonic germ cell development, and eventually will be able to efficiently direct embryonic stem cells down specific differentiation paths, to become virtually any tissue in the body [6] . This is the promise of embryonic stem cells.
Embryonic stem cells can differentiate directly into either male or female gametes [7, 8, 9, 10] . Varying the culture conditions can result in some haploid gene expression, although complete spermatogenesis has been difficult to achieve in vitro [11] . By combining cell culture with transplantation into the testis, male gametes have been derived directly from embryonic germ cells [10] . Functional ova have not been as definitively obtained, although follicle-like structures have been generated in vitro [7, 8] .
Spermatogonial stem cells
Adult spermatogenesis is a complex and tightly regulated process in which a small pool of germ-line stem cells develops to ultimately form spermatozoa [12] . These stem cells, called spermatogonial stem cells (SSCs) are found in the basal compartment of the seminiferous epithelium, where they adhere to the basement membrane. SSC self-renewal ensures the maintenance of the stem cell pool, while their differentiation generates a large number of germ cells. Therefore, a balance between SSC self-renewal and differentiation in the adult testis is essential to maintain normal spermatogenesis and fertility throughout life.
The existence of spermatogonial stem cells was postulated almost 40 years ago on the basis of morphological studies [13, 14, 15] and observations of spermatogenic damage following exposure to toxins. The early studies of Clermont [16, 17] on human spermatogenesis revealed two types of spermatogonia according to the staining pattern of their nucleus, the A dark and A pale spermatogonia. Both cell types are generally considered to be stem cells [17, 18] . A dark spermatogonia function as reverse stem cells that rarely divide but can be triggered to self-renew in cases of injury or disease, whereas A pale spermatogonia are renewing stem cells [16, 17, 18, 19] . A pale spermatogonia divide into B spermatogonia, which further divide into spermatocytes [17] .
Brinster and colleagues proved the existence of mouse spermatogonial stem cells by unique approaches [20, 21] . Work has progressed in many laboratories to isolate enriched populations of spermatogonial stem cells from various species ranging from mice to primates. Many urologists today bank a testicular biopsy from patients about to undergo chemotherapy, with the expectation that the technology will advance rapidly over the next 10 years and enable transplantation in the future.
Mouse spermatogonial stem cells and the steps of spermatogenesis
SSCs are composed of a subpopulation of type A spermatogonia called A single spermatogonia. In the adult male mouse, the SSCs comprise 0.03% of the total number of germ cells [22] .
A single spermatogonia are isolated cells that can self-renew or divide and differentiate into A paired spermatogonia. A paired spermatogonia are cell doublets that remain linked by a cytoplasmic bridge. They divide synchronously into chains of A aligned spermatogonia.
Thus, A single , A paired , and A aligned cells are called undifferentiated spermatogonia [12] .
A aligned spermatogonia differentiate into A1 spermatogonia, which undergo six divisions to become intermediate and B spermatogonia. B spermatogonia give rise to spermatocytes, which enter meiosis to produce haploid spermatids [12] .
Sertoli cells in the testis, a crucial component of the spermatogonial stem cell niche, produce glial cell line-derived neurotrophic factor (GDNF), a distant member of the TGF family, which controls SSC self renewal [23] . Several groups have reported that SSC proliferation in culture requires the addition of GDNF to freshly isolated germ cells [24, 25] . Other factors within the niche also influence the fate of SSCs, such as colony-stimulating factor 1 (CSF1), which is produced by Leydig cells and some peritubular myoid cells [26] , and also plays a role in SSC self-renewal.
Markers of human SSCs
Markers to characterize and identify human SSCs have been investigated over the past 10 years. The expression of the surface marker G protein coupled receptor 125 (GPR125) as a useful marker for the isolation, characterization, and culture of putative human SSCs was recently reported [27] . GPR125-positive cells are very rare, and may be A dark spermatogonia or a sub-population of the self-renewing A pale spermatogonia.
Human SSCs are also positive for some markers that have been identified in mouse
SSCs and other undifferentiated spermatogonia, including GFRA1, UCHL1(PGP9.5), ZBTB16(PLZF), and THY1(CD90) [28] [27]. We have also obtained evidence that THY1 is a potential surface marker for human SSCs [29] .
Pluripotency of human testis-derived ESC-like cells
Previous studies demonstrated that neonatal and adult germline stem cells (GSCs) can be self-reprogrammed into embryonic stem cell (ESC)-like cells, called germline-derived pluripotent stem cells [30, 31, 32, 33] . In addition, Conrad et al. [34] reported that pluripotent cells can be derived from human testis; the authors called these cells human adult GSCs (haGSCs). Other research groups subsequently claimed that ESC-like cells can be obtained from cultures of human testicular cells [35, 36, 37 ].
Conrad's group compared the global gene expression profile of hESCs and haGSCs, and concluded that the two populations have a similar gene expression profile, and thus, that the haGSCs are pluripotent. However, Ko's group claimed that the gene expression profile of haGSCs differs substantially from the pluripotent profile of hESCs [38] . The haGSCs were found to express high levels of the fibroblast markers SNA12 and ACTA2, but no NANOG, and low OCT4 and SOX2 levels [38] . These authors suggested that the haGSCs originated from fibroblast cells rather than pluripotent tissue, and concluded that they are very similar to a human testicular fibroblast cell line (hTFCs) [38] . Conrad's group argued that Ko et al's microarray data sets were not processed in parallel in the same experiment and were therefore not comparable, thereby suggesting that the similarity between haGSCs and hTFCs is inconclusive.
Ko et al's argument, however, is supported by experiments that have established the reproducibility of microarray results across different laboratories [39, 40, 41] , particularly when a common platform and set of procedures are used, indicating that microarray data that are not processed in parallel are comparable [42] . This fact justifies the utility of microarray repositories, such as the GEO database [43] , not only as a data warehouse but also as a resource for comparative and combinatory analyses of the microarray data from different laboratories. Thus, it can be safely concluded that the global gene expression analysis of haGSCs demonstrated that they resemble fibroblast hTFCs more that pluripotent hESCs.
Induced pluripotent stem (iPS) cells
Mammalian somatic cells can be reprogrammed to induce pluripotent stem cells (iPSCs) by introducing a small set of transcription factors: OCT3/4, SOX2, and KLF4, and sometimes C-MYC, or an alternative combination of OCT3/4, SOX2, LIN28, and NANOG [44, 45, 46, 47, 48, 49, 50, 51, 52] . Human iPSCs have remarkable similarities to human embryonic stem cells (hESCs) in terms of their morphology, culture, proliferation, gene expression, and ability to differentiate into mesoderm, endoderm, and ectoderm both in vitro and in teratoma assays in vivo [53, 54] . We induced iPS cells from adult human testicular tissue by introducing OCT4, SOX2, KLF4, and C-MYC, using lentiviral vectors [55] . In addition, we generated ES-like cells from 293FT cells by introducing OCT4, SOX2, NANOG, and LIN28 with lentiviral vectors [56] . We also generated iPSCs derived from the human testicular tissue of individuals with Klinefelter syndrome (KS, also called 47, XXY) [57] .
Germ cells from ESCs and iPSCs
Recent studies indicate that mouse [7, 8, 10, 58, 59] and human [60, 61] [ 47, 62, 63, 64, 65] ESCs can differentiate in vitro into oocyte-like or sperm-like cells.
The ability of iPSCs derived from reprogrammed adult somatic cells to generate germ cells has not been reported. However, human iPSCs derived from fetal somatic cells can differentiate into primordial germ cells (PGCs), further indicating the similarity of the iPSCs' potential to that of hESCs [47] . The hESCs can spontaneously differentiate into PGCs at low frequency, when factors that promote self-renewal, such as feeder cells and basic fibroblast growth factor, are removed [60, 66 ].
Kee's group reported the differentiation of hESCs into germ cells that initiated meiosis and progressed to form haploid germ cells. They showed that the overexpression of members of the DAZ gene family, DAZ, DAZL, and BOULE, promoted the induction of PGCs and the initiation of meiosis, to produce the haploid cells that are unique to germ cell development [65] . Panula's group reported that fetal-and adult-derived iPSCs can differentiate into germ cells [67] . They also found that ~5% of human iPSCs differentiate into PGCs following their induction with bone morphogenetic proteins [67] . In addition, Eguizabal's group reported the differentiation of human iPSCs to germ-like cells without the overexpression of development-related genes, in contrast to
Kee's group [68] .
The protocol of Eguizabal et al consists of three steps. First, human iPSCs and hESCs are allowed to differentiate for 3 weeks in a monolayer, in the absence of growth cytokines. Second, the cells are cultured for 3 weeks in the presence of retinoic acid.
Finally, after these 6 weeks of differentiation, the cells are sorted for a certain combination of surface markers (CD49f++, CD9+, CD90-, and SSEA4-), and the isolated fraction is cultured in the presence of leukemia inhibiting factor (LIF), bFGF, Forskolin (FRSK), and CYP26 inhibitor for 4 more weeks. Thus, the entire differentiation procedure is 10 weeks long [68] . The ability to generate germ cells without introducing retroviral vectors would be a remarkable advantage for using iPSCs in regenerative therapies to treat male infertility. These cells are also generated using the patient's own tissue, and do not have the same ethical concerns as ESCs.
Conclusions
Stem cell research has shown remarkable progress over the past 5 years. However, improvements are still needed before stem cells can be used clinically. For the treatment of male infertility, future advances may enable spermatids to be differentiated from germline stem cells or iPS cells.
